519 related articles for article (PubMed ID: 16039956)
1. Approaches to managing bone metastases from breast cancer: the role of bisphosphonates.
Mystakidou K; Katsouda E; Stathopoulou E; Vlahos L
Cancer Treat Rev; 2005 Jun; 31(4):303-11. PubMed ID: 16039956
[TBL] [Abstract][Full Text] [Related]
2. Managing metastatic bone pain: the role of bisphosphonates.
Gralow J; Tripathy D
J Pain Symptom Manage; 2007 Apr; 33(4):462-72. PubMed ID: 17397707
[TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapy of bone metastases in breast cancer patients.
Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of bisphosphonates in cancer therapy.
Lüftner D; Henschke P; Possinger K
Anticancer Res; 2007; 27(4A):1759-68. PubMed ID: 17649770
[TBL] [Abstract][Full Text] [Related]
5. Clinical trials in metastatic breast cancer to bone: past--present--future.
Body JJ
Can J Oncol; 1995 Dec; 5 Suppl 1():16-27. PubMed ID: 8853520
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate therapy for patients with breast carcinoma.
Plunkett TA; Rubens RD
Cancer; 2003 Feb; 97(3 Suppl):854-8. PubMed ID: 12548586
[TBL] [Abstract][Full Text] [Related]
7. The role of bisphosphonates in breast cancer.
Coleman RE
Breast; 2004 Dec; 13 Suppl 1():S19-28. PubMed ID: 15585379
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and cost of bisphosphonate therapy in tumor bone disease.
Body JJ
Cancer; 2003 Feb; 97(3 Suppl):859-65. PubMed ID: 12548587
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates and bone metastases: current status and future directions.
Krempien R; Niethammer A; Harms W; Debus J
Expert Rev Anticancer Ther; 2005 Apr; 5(2):295-305. PubMed ID: 15877526
[TBL] [Abstract][Full Text] [Related]
10. New results from the use of bisphosphonates in cancer patients.
Coleman R; Gnant M
Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
[TBL] [Abstract][Full Text] [Related]
11. Bone health management in patients with breast cancer: current standards and emerging strategies.
Aapro MS; Coleman RE
Breast; 2012 Feb; 21(1):8-19. PubMed ID: 21958673
[TBL] [Abstract][Full Text] [Related]
12. Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer.
Clemons M; Dranitsaris G; Cole D; Gainford MC
Oncologist; 2006 Mar; 11(3):227-33. PubMed ID: 16549806
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer: bisphosphonate therapy for metastatic bone disease.
Body JJ
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6258s-6263s. PubMed ID: 17062710
[TBL] [Abstract][Full Text] [Related]
14. [Current use of bisphosphonates in clinical oncology].
Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
[TBL] [Abstract][Full Text] [Related]
15. Optimal management of metastatic bone disease.
Major P
Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.
Rosen LS
Semin Oncol; 2002 Dec; 29(6 Suppl 21):28-32. PubMed ID: 12584692
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?
Freedman OC; Amir E; Clemons MJ
Crit Rev Oncol Hematol; 2009 Oct; 72(1):56-64. PubMed ID: 19307138
[TBL] [Abstract][Full Text] [Related]
18. Management of bisphosphonate treatment in clinical practice.
Aapro MS
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S28-32. PubMed ID: 18068488
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
20. How can we improve the treatment of bone metastases further?
Coleman RE
Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S7-13. PubMed ID: 9801853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
